Share Price and Basic Stock Data
Last Updated: January 22, 2026, 5:19 pm
| PEG Ratio | 4.86 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Advanced Enzyme Technologies Ltd, a key player in the pharmaceuticals sector, reported a current share price of ₹271 and a market capitalization of ₹3,033 Cr. The company has demonstrated a consistent upward trajectory in revenue, with sales rising from ₹529 Cr in March 2022 to ₹541 Cr in March 2023, and further increasing to ₹637 Cr in March 2025. The trailing twelve months (TTM) revenue stands at ₹707 Cr, indicating robust growth. Quarterly sales figures also reflect this trend, with revenues climbing from ₹139 Cr in September 2022 to ₹158 Cr in September 2023. The company’s operating profit margins (OPM) have stabilized around 33%, showcasing effective cost management in a competitive landscape. Overall, Advanced Enzyme Technologies appears well-positioned to continue its growth trajectory, supported by strong demand for its enzyme-based solutions across various applications.
Profitability and Efficiency Metrics
The company’s profitability metrics are encouraging, with a P/E ratio of 20.6 and a return on equity (ROE) of 9.54%. Advanced Enzyme Technologies recorded a net profit of ₹151 Cr, reflecting efficient operational management. Profitability has remained relatively stable, with quarterly net profits ranging from ₹26 Cr in September 2022 to ₹42 Cr in December 2023, and reaching ₹45 Cr in September 2025. The interest coverage ratio (ICR) stands impressively at 63.95x, indicating a strong ability to meet interest obligations. However, the cash conversion cycle (CCC) of 403 days suggests potential inefficiencies in working capital management. This extended cycle could pose challenges in liquidity and operational flexibility, contrasting with industry norms where lower CCC values are preferred. Overall, while Advanced Enzyme Technologies maintains solid profitability, improving efficiency in working capital management remains an area for focus.
Balance Sheet Strength and Financial Ratios
Advanced Enzyme Technologies boasts a strong balance sheet, with total assets reported at ₹1,611 Cr and minimal borrowings of ₹35 Cr, leading to a debt-to-equity ratio of 0.01. The company’s reserves have grown significantly, reaching ₹1,462 Cr, which enhances its financial stability and supports future growth initiatives. The current ratio is exceptionally high at 9.09, reflecting strong liquidity and the ability to cover short-term liabilities. Furthermore, the book value per share has increased to ₹127.00, indicating a solid foundation for shareholder value. However, the return on capital employed (ROCE) of 13% is moderate compared to sector averages, suggesting room for improvement in capital efficiency. The company’s financial ratios indicate a healthy balance sheet, but enhancing capital utilization could drive greater shareholder returns.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Advanced Enzyme Technologies reveals a diverse ownership structure, with promoters holding 43.08% and foreign institutional investors (FIIs) at 25.41%. This level of FII participation signals strong investor confidence in the company’s growth potential. Domestic institutional investors (DIIs) hold 6.41%, while the public accounts for 25.09%, with the number of shareholders increasing to 69,637 as of September 2025. The gradual decline in promoter shareholding from 49.88% in December 2022 to the current level may raise some concerns regarding management control, yet it could also indicate a strategic decision to broaden the ownership base. Overall, the mix of institutional and public investors suggests a stable confidence in Advanced Enzyme Technologies, bolstered by its consistent financial performance.
Outlook, Risks, and Final Insight
Looking ahead, Advanced Enzyme Technologies is well-positioned to leverage its strong financials and market position to drive growth. Key strengths include a robust revenue growth trajectory, high liquidity, and a healthy interest coverage ratio. However, risks such as the extended cash conversion cycle and moderate ROCE must be addressed to enhance operational efficiency. The company could benefit from strategic initiatives aimed at optimizing working capital and improving capital utilization. In scenarios where the company successfully reduces its cash conversion cycle, it may experience enhanced liquidity and operational flexibility, leading to improved profitability. Conversely, any significant disruptions in the supply chain or regulatory changes could present challenges. Overall, while the outlook remains positive, proactive management of identified risks will be crucial for sustaining growth and maximizing shareholder value.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 130 Cr. | 103 | 203/84.3 | 28.7 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.29/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 3,542 Cr. | 325 | 479/192 | 73.4 | 24.3 | 0.20 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 32.3 Cr. | 43.5 | 87.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 61.1 Cr. | 41.7 | 41.7/17.0 | 145 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,583.58 Cr | 1,090.30 | 47.80 | 202.32 | 0.38% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 139 | 142 | 139 | 147 | 158 | 161 | 158 | 155 | 146 | 169 | 167 | 186 | 185 |
| Expenses | 99 | 100 | 95 | 103 | 107 | 107 | 102 | 103 | 104 | 114 | 122 | 129 | 124 |
| Operating Profit | 40 | 42 | 44 | 44 | 51 | 54 | 55 | 51 | 42 | 55 | 46 | 56 | 60 |
| OPM % | 29% | 29% | 32% | 30% | 32% | 33% | 35% | 33% | 29% | 33% | 27% | 30% | 33% |
| Other Income | 4 | 9 | 7 | 7 | 6 | 14 | -6 | 7 | 10 | 8 | 9 | 9 | 10 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 9 | 9 | 8 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 10 | 10 | 10 |
| Profit before tax | 34 | 40 | 42 | 41 | 48 | 59 | 40 | 49 | 42 | 53 | 43 | 55 | 60 |
| Tax % | 23% | 31% | 24% | 29% | 27% | 28% | 25% | 28% | 21% | 27% | 38% | 26% | 25% |
| Net Profit | 26 | 28 | 32 | 29 | 35 | 42 | 30 | 35 | 33 | 39 | 27 | 40 | 45 |
| EPS in Rs | 2.34 | 2.63 | 2.87 | 2.58 | 3.08 | 3.74 | 2.53 | 3.05 | 2.94 | 3.37 | 2.37 | 3.57 | 3.87 |
Last Updated: January 2, 2026, 3:04 pm
Below is a detailed analysis of the quarterly data for Advanced Enzyme Technologies Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 185.00 Cr.. The value appears to be declining and may need further review. It has decreased from 186.00 Cr. (Jun 2025) to 185.00 Cr., marking a decrease of 1.00 Cr..
- For Expenses, as of Sep 2025, the value is 124.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 129.00 Cr. (Jun 2025) to 124.00 Cr., marking a decrease of 5.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 60.00 Cr.. The value appears strong and on an upward trend. It has increased from 56.00 Cr. (Jun 2025) to 60.00 Cr., marking an increase of 4.00 Cr..
- For OPM %, as of Sep 2025, the value is 33.00%. The value appears strong and on an upward trend. It has increased from 30.00% (Jun 2025) to 33.00%, marking an increase of 3.00%.
- For Other Income, as of Sep 2025, the value is 10.00 Cr.. The value appears strong and on an upward trend. It has increased from 9.00 Cr. (Jun 2025) to 10.00 Cr., marking an increase of 1.00 Cr..
- For Interest, as of Sep 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 1.00 Cr..
- For Depreciation, as of Sep 2025, the value is 10.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 10.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 60.00 Cr.. The value appears strong and on an upward trend. It has increased from 55.00 Cr. (Jun 2025) to 60.00 Cr., marking an increase of 5.00 Cr..
- For Tax %, as of Sep 2025, the value is 25.00%. The value appears to be improving (decreasing) as expected. It has decreased from 26.00% (Jun 2025) to 25.00%, marking a decrease of 1.00%.
- For Net Profit, as of Sep 2025, the value is 45.00 Cr.. The value appears strong and on an upward trend. It has increased from 40.00 Cr. (Jun 2025) to 45.00 Cr., marking an increase of 5.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 3.87. The value appears strong and on an upward trend. It has increased from 3.57 (Jun 2025) to 3.87, marking an increase of 0.30.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:42 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 239 | 222 | 293 | 329 | 391 | 420 | 444 | 502 | 529 | 541 | 624 | 637 | 707 |
| Expenses | 189 | 131 | 155 | 177 | 226 | 236 | 241 | 269 | 327 | 382 | 418 | 441 | 489 |
| Operating Profit | 50 | 91 | 138 | 152 | 165 | 184 | 203 | 233 | 203 | 158 | 206 | 196 | 217 |
| OPM % | 21% | 41% | 47% | 46% | 42% | 44% | 46% | 46% | 38% | 29% | 33% | 31% | 31% |
| Other Income | 1 | 1 | -3 | 3 | 1 | 5 | 6 | 9 | 6 | 21 | 21 | 33 | 36 |
| Interest | 13 | 9 | 8 | 4 | 9 | 5 | 4 | 3 | 3 | 3 | 4 | 5 | 3 |
| Depreciation | 10 | 9 | 9 | 13 | 18 | 21 | 26 | 29 | 35 | 35 | 35 | 37 | 39 |
| Profit before tax | 28 | 74 | 118 | 137 | 139 | 162 | 179 | 210 | 171 | 140 | 188 | 187 | 211 |
| Tax % | 23% | 31% | 35% | 32% | 33% | 28% | 26% | 28% | 28% | 26% | 27% | 28% | |
| Net Profit | 21 | 51 | 77 | 93 | 94 | 116 | 133 | 151 | 124 | 104 | 137 | 134 | 151 |
| EPS in Rs | 1.85 | 4.60 | 6.97 | 8.20 | 8.07 | 9.95 | 11.58 | 13.06 | 10.70 | 9.45 | 11.92 | 11.72 | 13.18 |
| Dividend Payout % | 6% | 4% | 3% | 5% | 6% | 6% | 5% | 7% | 9% | 11% | 43% | 44% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 142.86% | 50.98% | 20.78% | 1.08% | 23.40% | 14.66% | 13.53% | -17.88% | -16.13% | 31.73% | -2.19% |
| Change in YoY Net Profit Growth (%) | 0.00% | -91.88% | -30.20% | -19.70% | 22.33% | -8.75% | -1.12% | -31.41% | 1.75% | 47.86% | -33.92% |
Advanced Enzyme Technologies Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 7% |
| 3 Years: | 6% |
| TTM: | 6% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 0% |
| 3 Years: | 3% |
| TTM: | -8% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 8% |
| 3 Years: | 8% |
| 1 Year: | -25% |
| Return on Equity | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | 11% |
| 3 Years: | 10% |
| Last Year: | 10% |
Last Updated: September 4, 2025, 10:20 pm
Balance Sheet
Last Updated: December 4, 2025, 12:54 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 |
| Reserves | 145 | 188 | 256 | 442 | 537 | 657 | 817 | 949 | 1,066 | 1,213 | 1,302 | 1,398 | 1,462 |
| Borrowings | 167 | 115 | 101 | 54 | 67 | 35 | 28 | 28 | 35 | 34 | 47 | 39 | 35 |
| Other Liabilities | 73 | 92 | 71 | 65 | 102 | 91 | 104 | 150 | 137 | 142 | 150 | 151 | 173 |
| Total Liabilities | 406 | 417 | 450 | 583 | 727 | 805 | 971 | 1,149 | 1,260 | 1,411 | 1,521 | 1,611 | 1,692 |
| Fixed Assets | 287 | 287 | 285 | 421 | 491 | 495 | 563 | 604 | 619 | 649 | 650 | 679 | 683 |
| CWIP | 2 | 5 | 7 | 8 | 11 | 10 | 10 | 10 | 15 | 22 | 41 | 22 | 31 |
| Investments | 0 | 0 | 0 | 0 | 0 | 111 | 124 | 121 | 102 | 360 | 403 | 480 | 529 |
| Other Assets | 117 | 125 | 158 | 153 | 226 | 188 | 275 | 414 | 524 | 380 | 427 | 430 | 449 |
| Total Assets | 406 | 417 | 450 | 583 | 727 | 805 | 971 | 1,149 | 1,260 | 1,411 | 1,521 | 1,611 | 1,692 |
Below is a detailed analysis of the balance sheet data for Advanced Enzyme Technologies Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 22.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 22.00 Cr..
- For Reserves, as of Sep 2025, the value is 1,462.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,398.00 Cr. (Mar 2025) to 1,462.00 Cr., marking an increase of 64.00 Cr..
- For Borrowings, as of Sep 2025, the value is 35.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 39.00 Cr. (Mar 2025) to 35.00 Cr., marking a decrease of 4.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 173.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 151.00 Cr. (Mar 2025) to 173.00 Cr., marking an increase of 22.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 1,692.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,611.00 Cr. (Mar 2025) to 1,692.00 Cr., marking an increase of 81.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 683.00 Cr.. The value appears strong and on an upward trend. It has increased from 679.00 Cr. (Mar 2025) to 683.00 Cr., marking an increase of 4.00 Cr..
- For CWIP, as of Sep 2025, the value is 31.00 Cr.. The value appears strong and on an upward trend. It has increased from 22.00 Cr. (Mar 2025) to 31.00 Cr., marking an increase of 9.00 Cr..
- For Investments, as of Sep 2025, the value is 529.00 Cr.. The value appears strong and on an upward trend. It has increased from 480.00 Cr. (Mar 2025) to 529.00 Cr., marking an increase of 49.00 Cr..
- For Other Assets, as of Sep 2025, the value is 449.00 Cr.. The value appears strong and on an upward trend. It has increased from 430.00 Cr. (Mar 2025) to 449.00 Cr., marking an increase of 19.00 Cr..
- For Total Assets, as of Sep 2025, the value is 1,692.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,611.00 Cr. (Mar 2025) to 1,692.00 Cr., marking an increase of 81.00 Cr..
Notably, the Reserves (1,462.00 Cr.) exceed the Borrowings (35.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -117.00 | -24.00 | 37.00 | 98.00 | 98.00 | 149.00 | 175.00 | 205.00 | 168.00 | 124.00 | 159.00 | 157.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 49 | 61 | 52 | 55 | 55 | 51 | 61 | 63 | 61 | 68 | 58 | 66 |
| Inventory Days | 387 | 403 | 358 | 352 | 339 | 363 | 361 | 346 | 402 | 343 | 375 | 378 |
| Days Payable | 81 | 89 | 68 | 57 | 78 | 46 | 43 | 56 | 60 | 67 | 40 | 41 |
| Cash Conversion Cycle | 356 | 374 | 342 | 351 | 315 | 369 | 379 | 353 | 404 | 344 | 393 | 403 |
| Working Capital Days | -54 | -43 | 3 | 76 | 47 | 72 | 90 | 94 | 116 | 109 | 102 | 112 |
| ROCE % | 12% | 25% | 36% | 31% | 25% | 24% | 22% | 22% | 15% | 12% | 15% | 13% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| UTI MNC Fund | 1,037,821 | 1.13 | 32.35 | N/A | N/A | N/A |
| ICICI Prudential ESG Exclusionary Strategy Fund | 872,022 | 1.8 | 27.18 | N/A | N/A | N/A |
| Bank of India Small Cap Fund | 230,000 | 0.36 | 7.17 | 270,000 | 2025-12-14 08:30:11 | -14.81% |
| Bank of India ELSS Tax Saver | 190,000 | 0.42 | 5.92 | 200,000 | 2025-12-15 03:35:01 | -5% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
| Basic EPS (Rs.) | 11.72 | 11.92 | 9.45 | 10.70 | 13.09 |
| Diluted EPS (Rs.) | 11.71 | 11.92 | 9.45 | 10.68 | 13.07 |
| Cash EPS (Rs.) | 15.24 | 15.40 | 12.42 | 14.20 | 16.10 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 127.00 | 122.61 | 114.84 | 102.00 | 92.25 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 127.00 | 122.61 | 114.84 | 102.00 | 92.25 |
| Revenue From Operations / Share (Rs.) | 56.93 | 55.79 | 48.35 | 47.35 | 44.92 |
| PBDIT / Share (Rs.) | 20.33 | 21.56 | 16.27 | 18.59 | 21.51 |
| PBIT / Share (Rs.) | 17.06 | 18.41 | 13.13 | 15.46 | 18.97 |
| PBT / Share (Rs.) | 16.75 | 16.80 | 12.55 | 15.30 | 18.83 |
| Net Profit / Share (Rs.) | 11.97 | 12.25 | 9.29 | 11.07 | 13.56 |
| NP After MI And SOA / Share (Rs.) | 11.72 | 11.92 | 9.45 | 10.70 | 13.08 |
| PBDIT Margin (%) | 35.71 | 38.64 | 33.64 | 39.26 | 47.89 |
| PBIT Margin (%) | 29.97 | 33.00 | 27.16 | 32.65 | 42.23 |
| PBT Margin (%) | 29.41 | 30.10 | 25.96 | 32.31 | 41.91 |
| Net Profit Margin (%) | 21.03 | 21.95 | 19.21 | 23.38 | 30.18 |
| NP After MI And SOA Margin (%) | 20.58 | 21.36 | 19.53 | 22.58 | 29.13 |
| Return on Networth / Equity (%) | 9.22 | 10.06 | 8.55 | 10.98 | 15.06 |
| Return on Capital Employeed (%) | 12.52 | 14.40 | 10.92 | 14.31 | 19.53 |
| Return On Assets (%) | 8.08 | 8.68 | 7.42 | 9.43 | 12.68 |
| Long Term Debt / Equity (X) | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Total Debt / Equity (X) | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Asset Turnover Ratio (%) | 0.40 | 0.42 | 0.33 | 0.32 | 0.38 |
| Current Ratio (X) | 9.09 | 7.61 | 9.31 | 10.00 | 7.64 |
| Quick Ratio (X) | 7.47 | 6.22 | 7.71 | 8.00 | 6.25 |
| Inventory Turnover Ratio (X) | 4.17 | 1.14 | 1.23 | 1.30 | 1.32 |
| Dividend Payout Ratio (NP) (%) | 43.49 | 41.94 | 10.58 | 8.41 | 4.58 |
| Dividend Payout Ratio (CP) (%) | 34.01 | 33.17 | 7.94 | 6.50 | 3.83 |
| Earning Retention Ratio (%) | 56.51 | 58.06 | 89.42 | 91.59 | 95.42 |
| Cash Earning Retention Ratio (%) | 65.99 | 66.83 | 92.06 | 93.50 | 96.17 |
| Interest Coverage Ratio (X) | 63.95 | 82.35 | 75.13 | 115.72 | 150.80 |
| Interest Coverage Ratio (Post Tax) (X) | 38.66 | 52.94 | 45.58 | 69.93 | 96.02 |
| Enterprise Value (Cr.) | 3081.99 | 3814.49 | 2529.42 | 2942.98 | 3729.91 |
| EV / Net Operating Revenue (X) | 4.84 | 6.11 | 4.68 | 5.56 | 7.43 |
| EV / EBITDA (X) | 13.55 | 15.82 | 13.91 | 14.16 | 15.52 |
| MarketCap / Net Operating Revenue (X) | 4.90 | 6.23 | 4.79 | 5.96 | 7.68 |
| Retention Ratios (%) | 56.50 | 58.05 | 89.41 | 91.58 | 95.41 |
| Price / BV (X) | 2.20 | 2.93 | 2.10 | 2.90 | 3.97 |
| Price / Net Operating Revenue (X) | 4.90 | 6.23 | 4.79 | 5.96 | 7.68 |
| EarningsYield | 0.04 | 0.03 | 0.04 | 0.03 | 0.03 |
After reviewing the key financial ratios for Advanced Enzyme Technologies Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 2.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 11.72. This value is within the healthy range. It has decreased from 11.92 (Mar 24) to 11.72, marking a decrease of 0.20.
- For Diluted EPS (Rs.), as of Mar 25, the value is 11.71. This value is within the healthy range. It has decreased from 11.92 (Mar 24) to 11.71, marking a decrease of 0.21.
- For Cash EPS (Rs.), as of Mar 25, the value is 15.24. This value is within the healthy range. It has decreased from 15.40 (Mar 24) to 15.24, marking a decrease of 0.16.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 127.00. It has increased from 122.61 (Mar 24) to 127.00, marking an increase of 4.39.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 127.00. It has increased from 122.61 (Mar 24) to 127.00, marking an increase of 4.39.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 56.93. It has increased from 55.79 (Mar 24) to 56.93, marking an increase of 1.14.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 20.33. This value is within the healthy range. It has decreased from 21.56 (Mar 24) to 20.33, marking a decrease of 1.23.
- For PBIT / Share (Rs.), as of Mar 25, the value is 17.06. This value is within the healthy range. It has decreased from 18.41 (Mar 24) to 17.06, marking a decrease of 1.35.
- For PBT / Share (Rs.), as of Mar 25, the value is 16.75. This value is within the healthy range. It has decreased from 16.80 (Mar 24) to 16.75, marking a decrease of 0.05.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 11.97. This value is within the healthy range. It has decreased from 12.25 (Mar 24) to 11.97, marking a decrease of 0.28.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 11.72. This value is within the healthy range. It has decreased from 11.92 (Mar 24) to 11.72, marking a decrease of 0.20.
- For PBDIT Margin (%), as of Mar 25, the value is 35.71. This value is within the healthy range. It has decreased from 38.64 (Mar 24) to 35.71, marking a decrease of 2.93.
- For PBIT Margin (%), as of Mar 25, the value is 29.97. This value exceeds the healthy maximum of 20. It has decreased from 33.00 (Mar 24) to 29.97, marking a decrease of 3.03.
- For PBT Margin (%), as of Mar 25, the value is 29.41. This value is within the healthy range. It has decreased from 30.10 (Mar 24) to 29.41, marking a decrease of 0.69.
- For Net Profit Margin (%), as of Mar 25, the value is 21.03. This value exceeds the healthy maximum of 10. It has decreased from 21.95 (Mar 24) to 21.03, marking a decrease of 0.92.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 20.58. This value exceeds the healthy maximum of 20. It has decreased from 21.36 (Mar 24) to 20.58, marking a decrease of 0.78.
- For Return on Networth / Equity (%), as of Mar 25, the value is 9.22. This value is below the healthy minimum of 15. It has decreased from 10.06 (Mar 24) to 9.22, marking a decrease of 0.84.
- For Return on Capital Employeed (%), as of Mar 25, the value is 12.52. This value is within the healthy range. It has decreased from 14.40 (Mar 24) to 12.52, marking a decrease of 1.88.
- For Return On Assets (%), as of Mar 25, the value is 8.08. This value is within the healthy range. It has decreased from 8.68 (Mar 24) to 8.08, marking a decrease of 0.60.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.01. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.01.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.01. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.01.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.40. It has decreased from 0.42 (Mar 24) to 0.40, marking a decrease of 0.02.
- For Current Ratio (X), as of Mar 25, the value is 9.09. This value exceeds the healthy maximum of 3. It has increased from 7.61 (Mar 24) to 9.09, marking an increase of 1.48.
- For Quick Ratio (X), as of Mar 25, the value is 7.47. This value exceeds the healthy maximum of 2. It has increased from 6.22 (Mar 24) to 7.47, marking an increase of 1.25.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 4.17. This value is within the healthy range. It has increased from 1.14 (Mar 24) to 4.17, marking an increase of 3.03.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 43.49. This value is within the healthy range. It has increased from 41.94 (Mar 24) to 43.49, marking an increase of 1.55.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 34.01. This value is within the healthy range. It has increased from 33.17 (Mar 24) to 34.01, marking an increase of 0.84.
- For Earning Retention Ratio (%), as of Mar 25, the value is 56.51. This value is within the healthy range. It has decreased from 58.06 (Mar 24) to 56.51, marking a decrease of 1.55.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 65.99. This value is within the healthy range. It has decreased from 66.83 (Mar 24) to 65.99, marking a decrease of 0.84.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 63.95. This value is within the healthy range. It has decreased from 82.35 (Mar 24) to 63.95, marking a decrease of 18.40.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 38.66. This value is within the healthy range. It has decreased from 52.94 (Mar 24) to 38.66, marking a decrease of 14.28.
- For Enterprise Value (Cr.), as of Mar 25, the value is 3,081.99. It has decreased from 3,814.49 (Mar 24) to 3,081.99, marking a decrease of 732.50.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 4.84. This value exceeds the healthy maximum of 3. It has decreased from 6.11 (Mar 24) to 4.84, marking a decrease of 1.27.
- For EV / EBITDA (X), as of Mar 25, the value is 13.55. This value is within the healthy range. It has decreased from 15.82 (Mar 24) to 13.55, marking a decrease of 2.27.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 4.90. This value exceeds the healthy maximum of 3. It has decreased from 6.23 (Mar 24) to 4.90, marking a decrease of 1.33.
- For Retention Ratios (%), as of Mar 25, the value is 56.50. This value is within the healthy range. It has decreased from 58.05 (Mar 24) to 56.50, marking a decrease of 1.55.
- For Price / BV (X), as of Mar 25, the value is 2.20. This value is within the healthy range. It has decreased from 2.93 (Mar 24) to 2.20, marking a decrease of 0.73.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 4.90. This value exceeds the healthy maximum of 3. It has decreased from 6.23 (Mar 24) to 4.90, marking a decrease of 1.33.
- For EarningsYield, as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. It has increased from 0.03 (Mar 24) to 0.04, marking an increase of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Advanced Enzyme Technologies Ltd:
- Net Profit Margin: 21.03%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 12.52% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 9.22% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 38.66
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 7.47
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 20.7 (Industry average Stock P/E: 47.8)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.01
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 21.03%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | A - Wing, Sun Magnetica, 5th Floor, LIC Service Road, Thane Maharashtra 400604 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Vasant Rathi | Non Executive Chairman |
| Mr. Mukund Kabra | Whole Time Director |
| Ms. Rasika Rathi | Non Executive Director |
| Dr. Sunny Sharma | Non Executive Director |
| Mr. Pramod Kasat | Independent Director |
| Mrs. Vandana Tilak | Independent Director |
| Ms. Rajshree Patel | Independent Director |
| Mr. Nitin Desmukh | Independent Director |
| Mr. Vinodkumar Jajoo | Independent Director |
FAQ
What is the intrinsic value of Advanced Enzyme Technologies Ltd?
Advanced Enzyme Technologies Ltd's intrinsic value (as of 22 January 2026) is ₹223.25 which is 17.92% lower the current market price of ₹272.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹3,052 Cr. market cap, FY2025-2026 high/low of ₹367/258, reserves of ₹1,462 Cr, and liabilities of ₹1,692 Cr.
What is the Market Cap of Advanced Enzyme Technologies Ltd?
The Market Cap of Advanced Enzyme Technologies Ltd is 3,052 Cr..
What is the current Stock Price of Advanced Enzyme Technologies Ltd as on 22 January 2026?
The current stock price of Advanced Enzyme Technologies Ltd as on 22 January 2026 is ₹272.
What is the High / Low of Advanced Enzyme Technologies Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Advanced Enzyme Technologies Ltd stocks is ₹367/258.
What is the Stock P/E of Advanced Enzyme Technologies Ltd?
The Stock P/E of Advanced Enzyme Technologies Ltd is 20.7.
What is the Book Value of Advanced Enzyme Technologies Ltd?
The Book Value of Advanced Enzyme Technologies Ltd is 133.
What is the Dividend Yield of Advanced Enzyme Technologies Ltd?
The Dividend Yield of Advanced Enzyme Technologies Ltd is 1.91 %.
What is the ROCE of Advanced Enzyme Technologies Ltd?
The ROCE of Advanced Enzyme Technologies Ltd is 13.1 %.
What is the ROE of Advanced Enzyme Technologies Ltd?
The ROE of Advanced Enzyme Technologies Ltd is 9.54 %.
What is the Face Value of Advanced Enzyme Technologies Ltd?
The Face Value of Advanced Enzyme Technologies Ltd is 2.00.